HES1 and non-small cell lung carcinoma: Also accordingly, HES1 downstream target of NOTCH1, strongly correlated in the CTCs immunoisolated from advanced NSCLC patients, further suggesting the functional involvement of Notch pathway and the potential therapeutic value of Notch pathway-directed drugs such as γ-secretase inhibitors or ADAM inhibitors in advanced NSCLC35, 36.